Company: PTPI
Filing Date: 2025-02-19
Form Type: 424B4
Source: 0001410578-25-000164
Chunk: 19

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-19
Form: 424B4
Chunk 19
---
 expire on the one (1) year anniversary of the Initial Exercise Date.The shares of common stock and Pre-Funded Warrants, and the accompanying Series Warrants, as the case may be, can only be purchased together in this offering but will be issued separately.This prospectus also relates to the offering of the shares of common stock issuable upon exercise of the Series B Warrants. Because we will issue a Series B Warrant for each share of common stock and for each Pre-Funded Warrant sold in this offering, the number of Series B Warrants sold in this offering will not change as a result of a change in the mix of the shares of our common stock and Pre-Funded Warrants sold.Holders the Series B Warrants may effect an “alternative cashless exercise” at any time while the Series B Warrants are outstanding following the Initial Exercise Date. Under the alternative cashless exercise option, a holder of a Series B Warrant has the right to receive an aggregate number of shares of common stock equal to the product of (i) the aggregate number of shares of common stock that would be issuable upon a cash rather than a cashless exercise of the Series B Warrant and (ii) 3.0. Accordingly, it is highly unlikely that a holder of the Series B Warrants would wish to pay an exercise price in cash to receive one share of common stock when they could instead choose the alternative cashless exercise option and pay no cash to receive three shares of common stock. As a result, we will likely not receive any additional funds and do not expect to receive any additional funds upon the exercise of the Series B Warrants. |

| Common stock outstanding prior to this offering    | ​ | 11,319,039 shares.                                                                                                                                        |
| Common stock to be outstanding after this offering |   | 51,319,039 shares (assuming the full exercise of the Pre-Funded Warrants and assuming none of the Series Warrants issued in this offering are exercised). |

| Use of proceeds |     | We estimate that the net proceeds to us from this offering will be approximately $8.5 million, after deducting the Placement Agent fees and estimated offering expenses payable by us and assuming no exercise of the Series Warrants. We intend to use the net proceeds from the sale of the securities for working capital and general corporate purposes. See “Use of Proceeds” on page 41 of this prospectus. |

| Risk factors |     | You should carefully read and consider the information set forth under “